Cost Effectiveness of Renal Denervation Therapy for the Treatment of Resistant Hypertension in the UK

Applied Health Economics and Health Policy

Volumn 12, Issue 6, 2014, Pages 611-622

  Gladwell, Daniel ^a   Henry, Thea ^a   Cook, Mark ^b   Akehurst, Ron ^a  

^a BRESMED   (United Kingdom)

^b Medtronic Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HUMAN; KIDNEY DENERVATION; MALE; MORTALITY; QUALITY ADJUSTED LIFE YEAR; RESISTANT HYPERTENSION; SYSTOLIC BLOOD PRESSURE; UNITED KINGDOM; CATHETERIZATION; COMPLICATION; COST BENEFIT ANALYSIS; ECONOMICS; HYPERTENSION; INNERVATION; KIDNEY; MIDDLE AGED; PROBABILITY; PROCEDURES; STATISTICAL MODEL; SYMPATHECTOMY;

AGED; CATHETERIZATION; COST-BENEFIT ANALYSIS; FEMALE; GREAT BRITAIN; HUMANS; HYPERTENSION; KIDNEY; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; SYMPATHECTOMY;

EID: 84911967721     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-014-0116-7     Document Type: Article

References (45)

1. Brindle P, Emberson J, Lampe F, Walker M, Whincup P, Fahey T, et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ. 2003;327(7426):1267.
2. Sarafidis PA, Bakris GL. Resistant hypertension an overview of evaluation and treatment. J Am Coll Cardiol. 2008;52(22):1749–57.
3. Joint Health Surveys Unit. Health survey for England 2003. Volume 2. Risk factors for cardiovascular disease. 2004 [cited December 2012]. Available from: http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/publicationsandstatistics/publications/publicationsstatistics/dh_4098712.
4. National Institute for Health and Clinical Excellence (NICE). Hypertension: management of hypertension in adults in primary care (CG34). 2006 [cited December 2012]. Available from: http://www.nice.org.uk/guidance/index.jsp?action=byID&r=true&o=10986.
5. Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. Hypertension. 2011;57(6):1076–80.
6. Caulfield M, de Belder M, Cleveland T, Collier D, Deanfield J, Gray H, et al. The joint UK societies’ consensus statement on renal denervation for resistant hypertension. 2012 [cited January 2014]. Available from: http://www.bhsoc.org/docs/The-Joint-UK-Societies’-Consensus-on-Renal-Denervation-for-resistant-hypertension.pdf.
7. Schlaich MP, Schmieder RE, Bakris G, Blankestijn PJ, Bohm M, Campese VM, et al. International expert consensus statement: percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol. 2013;62(22):2031–45.
8. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275–81.
9. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet. 2010;376(9756):1903–9.
10. Symplicity HTNI. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57(5):911–7.
11. Geisler BP, Egan BM, Cohen JT, Garner AM, Akehurst RL, Esler MD, et al. Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension. J Am Coll Cardiol. 2012;60(14):1271–7.
12. Office of National Statistics (ONS). Interim life tables 2010–2012. 2013 [cited January 2014]. Available from: http://www.ons.gov.uk.
13. Saposnik G, Hill MD, O’Donnell M, Fang J, Hachinski V, Kapral MK, et al. Variables associated with 7-day, 30-day, and 1-year fatality after ischemic stroke. Stroke. 2008;39(8):2318–24.
14. Haeusler KG, Laufs U, Endres M. Chronic heart failure and ischemic stroke. Stroke. 2011;42(10):2977–82.
15. Witt BJ, Brown RD Jr, Jacobsen SJ, Weston SA, Yawn BP, Roger VL. A community-based study of stroke incidence after myocardial infarction. Ann Intern Med. 2005;143(11):785–92.
16. Tengs TO, Lin TH. A meta-analysis of quality-of-life estimates for stroke. Pharmacoeconomics. 2003;21(3):191–200.
17. Barakat K, Wilkinson P, Deaner A, Fluck D, Ranjadayalan K, Timmis A. How should age affect management of acute myocardial infarction? A prospective cohort study. Lancet. 1999;353(9157):955–9.
18. Rogers WJ, Frederick PD, Stoehr E, Canto JG, Ornato JP, Gibson CM, et al. Trends in presenting characteristics and hospital mortality among patients with ST elevation and non-ST elevation myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. Am Heart J. 2008;156(6):1026–34.
19. Flack JM, Neaton J, Grimm R Jr, Shih J, Cutler J, Ensrud K, et al. Blood pressure and mortality among men with prior myocardial infarction: Multiple Risk Factor Intervention Trial Research Group. Circulation. 1995;92(9):2437–45.
20. Melsop KA, Boothroyd DB, Hlatky MA. Quality of life and time trade-off utility measures in patients with coronary artery disease. Am Heart J. 2003;145(1):36–41.
21. ERA-EDTA Registry. ERA-EDTA Registry Annual Report 2010. 2012 [cited December 2012]. Available from: http://www.era-edta-reg.org/files/annualreports/pdf/AnnRep2010.pdf.
22. Hoerger T, Richter A, Bethke A, Gibbons C. A Markov model of disease progression and cost-effectiveness for type 2 diabetes (technical report). Ann Intern Med. 2002.
23. Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess. 2007;11(14):1–160 (iii–iv).
24. Goodacre S, Nicholl J, Dixon S, Cross E, Angelini K, Arnold J, et al. Randomised controlled trial and economic evaluation of a chest pain observation unit compared with routine care. BMJ. 2004;328(7434):254.
25. Comin-Colet J, Lainscak M, Dickstein K, Filippatos GS, Johnson P, Luscher TF, et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study. Eur Heart J. 2013;34(1):30–8.
26. Glasziou P, Alexander J, Beller E, Clarke P, Group AC. Which health-related quality of life score? A comparison of alternative utility measures in patients with type 2 diabetes in the ADVANCE trial. Health Qual Life Outcomes. 2007;5:21.
27. Gorodetskaya I, Zenios S, McCulloch CE, Bostrom A, Hsu CY, Bindman AB, et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int. 2005;68(6):2801–8.
28. National Institute for Health and Clinical Excellence (NICE). Hypertension: clinical management of primary hypertension in adults (CG24). 2011 [cited 15 January 2014]. Available from: http://www.nice.org.uk/nicemedia/live/13561/56008/56008.pdf.
29. Youman P, Wilson K, Harraf F, Kalra L. The economic burden of stroke in the United Kingdom. Pharmacoeconomics. 2003;21(Suppl 1):43–50.
30. National Health Service (NHS). Blood and transplant. Fact sheet 7: cost-effectiveness of transplantation. 2009 [cited December 2012]. Available from: http://www.organdonation.nhs.uk/newsroom/fact_sheets/organ_donation_registry_fact_sheet_7_21337.pdf.
31. Joint Formulary Committee. British National Formulary. 63 ed. 2012 [cited December 2012]. Available from: http://www.bnf.org/bnf/index.htm.
32. Curtis L. Unit costs of health and social care 2012: Personal Social Services Research Unit. 2012 [cited December 2012]. Available from: http://www.pssru.ac.uk.
33. Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–47.
34. D’Agostino RB, Russell MW, Huse DM, Ellison RC, Silbershatz H, Wilson PW, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J. 2000;139(2 Pt 1):272–81.
35. Hsu CY, Vittinghoff E, Lin F, Shlipak MG. The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med. 2004;141(2):95–101.
36. Divani AA, Vazquez G, Asadollahi M, Qureshi AI, Pullicino P. Nationwide frequency and association of heart failure on stroke outcomes in the United States. J Cardiac Fail. 2009;15(1):11–6.
37. Kandzari DE, Bhatt DL, Sobotka PA, O’Neill WW, Esler M, Flack JM, et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the Symplicity HTN-3 trial. Clin Cardiol. 2012;35(9):528–35.
38. Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJ, Swedberg KB, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006;27(1):65–75.
39. Krum H, Schlaich MP, Sobotka PA, Bohm M, Mahfoud F, Rocha-Singh K, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383(9917):622–9.
40. National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal. 2008 [cited December 2012]. Available from: http://www.nice.org.uk/media/b52/a7/tamethodsguideupdatedjune2008.pdf.
41. Banach M, Nikfar S, Rahimi R, Bielecka-Dabrowa A, Pencina MJ, Mikhailidis DP, et al. The effects of statins on blood pressure in normotensive or hypertensive subjects: a meta-analysis of randomized controlled trials. Int J Cardiol. 2013;168(3):2816–24.
42. Strazzullo P, Kerry SM, Barbato A, Versiero M, D’Elia L, Cappuccio FP. Do statins reduce blood pressure? A meta-analysis of randomized, controlled trials. Hypertension. 2007;49(4):792–8.
43. Golomb BA, Dimsdale JE, White HL, Ritchie JB, Criqui MH. Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial. Arch Intern Med. 2008;168(7):721–7.
44. Health and Social Care Information Centre. Health survey for England: 2011, trend tables [NS]. 2012 [cited January 2014]. Available from: http://www.hscic.gov.uk/catalogue/PUB09302.
45. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51(6):1403–19.